The nation’s leading cancer research institute is now investigating ivermectin – a drug primarily used to deworm animals – as a potential cancer treatment. This surprising turn comes amidst a growing wave of interest fueled by unsubstantiated claims and a rising distrust of conventional medicine.
Dr. Anthony Letai, director of the National Cancer Institute, revealed the agency initiated a preclinical study to examine ivermectin’s ability to kill cancer cells. He acknowledged the research wasn’t prompted by new, definitive evidence, but by the sheer volume of public discussion surrounding the drug.
The decision has ignited alarm within the scientific community. One NCI scientist, speaking anonymously out of fear of reprisal, described the move as “shocking and appalling,” arguing that valuable resources are being diverted from promising research based on “nonscientific ideas.”
This investigation unfolds against a backdrop of the “Make America Healthy Again” agenda, championed by Health and Human Services Secretary Robert F. Kennedy Jr., and a movement that views ivermectin as a symbol of resistance against established medical authorities. During the COVID-19 pandemic, the drug gained notoriety as a falsely promoted treatment, despite clinical trials proving its ineffectiveness.
The National Institutes of Health Director, Jay Bhattacharya, stated the NIH has an “obligation” to seriously consider ideas gaining public traction, even if they challenge scientific consensus. He recently expressed a desire for the NIH to function as “the research arm of MAHA,” raising concerns about the influence of ideology on scientific inquiry.
While previous lab studies hinted at ivermectin’s potential to promote cell death in cancer cells, there’s currently no evidence of its safety or efficacy in treating the disease in humans. A small clinical trial combining ivermectin with immunotherapy for metastatic breast cancer showed no significant benefit.
Oncologists are increasingly concerned that patients, swayed by misinformation circulating on social media, may delay or abandon proven cancer treatments in favor of ivermectin. One physician recounted persuading a patient to discontinue its use, while another described a patient choosing ivermectin over “highly effective standard therapy.”
The dangers of ivermectin misuse are real. The FDA has warned that high doses can lead to seizures, comas, and even death. A recent case involved an adolescent cancer patient experiencing severe neurotoxicity after self-treating with the drug based on social media recommendations.
Despite the lack of evidence, influential figures continue to promote ivermectin as a miracle cure. Actor Mel Gibson recently claimed on a popular podcast that the drug cured three friends with stage 4 cancer, reaching an audience of over 12 million. Several states have even moved to make the drug available over the counter.
Dr. Letai attempted to manage expectations, stating that ivermectin is unlikely to be a “cure-all for cancer.” However, the decision to allocate resources to this investigation underscores a shift within the NIH towards a greater willingness to explore unconventional ideas, even those dismissed by the scientific establishment.
Another NCI scientist, also speaking anonymously, dismissed the notion that the NIH was previously closed off to investigating alternative therapies. The core issue, they implied, isn’t a lack of openness, but the justification for diverting funds to a study based on questionable premises.
The specifics of the NCI’s ivermectin research – including funding amounts and the institutions involved – remain undisclosed. As the study progresses, the scientific community watches with a mixture of apprehension and a commitment to rigorous, evidence-based medicine.
The current climate reflects a “fundamental mistrust of medicine,” according to one oncologist, who emphasized the ongoing struggle to combat misinformation and maintain patient trust in proven treatments. The challenge, he said, is to “keep trying” to reach those who have already made up their minds.
